Literature DB >> 33514684

All-trans retinoic acid 45 mg/m2 is superior to 25 mg/m2 as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting.

Xinhui Zhang1, Shanglong Feng1,2, Jin Xu3, Na Zhao2, Xing Hu2, Li Zhou2, Juan Tong2, Lei Xue2, Lei Zhang2, Yongsheng Han2, Xingbing Wang2, Liangquan Geng2, Xiaoyu Zhu2, Baolin Tang2, Huilan Liu2, Weibo Zhu2, Xiaoyan Cai2, Xin Liu2, Zimin Sun2, Changcheng Zheng4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33514684      PMCID： PMC7846739          DOI： 10.1038/s41408-021-00411-9

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  15 in total

1.  Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Authors:  Simon Mantha; Debra A Goldman; Sean M Devlin; Ju-Whei Lee; Diana Zannino; Marnie Collins; Dan Douer; Harry J Iland; Mark R Litzow; Eytan M Stein; Frederick R Appelbaum; Richard A Larson; Richard Stone; Bayard L Powell; Susan Geyer; Kristina Laumann; Jacob M Rowe; Harry Erba; Steven Coutre; Megan Othus; Jae H Park; Peter H Wiernik; Martin S Tallman
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

Review 2.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Authors:  Miguel A Sanz; Pierre Fenaux; Martin S Tallman; Elihu H Estey; Bob Löwenberg; Tomoki Naoe; Eva Lengfelder; Hartmut Döhner; Alan K Burnett; Sai-Juan Chen; Vikram Mathews; Harry Iland; Eduardo Rego; Hagop Kantarjian; Lionel Adès; Giuseppe Avvisati; Pau Montesinos; Uwe Platzbecker; Farhad Ravandi; Nigel H Russell; Francesco Lo-Coco
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

3.  Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.

Authors:  Hong-Hu Zhu; De-Pei Wu; Xin Du; Xi Zhang; Lin Liu; Jun Ma; Zong-Hong Shao; Han-Yun Ren; Jian-Da Hu; Kai-Lin Xu; Jing-Wen Wang; Yong-Ping Song; Mei-Yun Fang; Juan Li; Xiao-Yan Yan; Xiao-Jun Huang
Journal:  Lancet Oncol       Date:  2018-06-05       Impact factor: 41.316

4.  Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.

Authors:  Hong-Hu Zhu; De-Pei Wu; Jie Jin; Jian-Yong Li; Jun Ma; Jian-Xiang Wang; Hao Jiang; Sai-Juan Chen; Xiao-Jun Huang
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

5.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Authors:  Jae H Park; Baozhen Qiao; Katherine S Panageas; Maria J Schymura; Joseph G Jurcic; Todd L Rosenblat; Jessica K Altman; Dan Douer; Jacob M Rowe; Martin S Tallman
Journal:  Blood       Date:  2011-06-08       Impact factor: 22.113

6.  Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study.

Authors:  Kristjan Paulson; Anna Serebrin; Pascal Lambert; Julie Bergeron; Janeve Everett; Andrea Kew; David Jones; Salah Mahmud; Catherine Meloche; Mitchell Sabloff; Ismail Sharif; John Storring; Donna Turner; Matthew D Seftel
Journal:  Br J Haematol       Date:  2014-04-30       Impact factor: 6.998

7.  Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

Authors:  James Scott McClellan; Holbrook E Kohrt; Steven Coutre; Jason R Gotlib; Ravindra Majeti; Ash A Alizadeh; Bruno C Medeiros
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

8.  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; David Bowen; Jonathan Kell; Steve Knapper; Yvonne G Morgan; Jennie Lok; Angela Grech; Gail Jones; Asim Khwaja; Lone Friis; Mary Frances McMullin; Ann Hunter; Richard E Clark; David Grimwade
Journal:  Lancet Oncol       Date:  2015-09-14       Impact factor: 41.316

9.  Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.

Authors:  Pau Montesinos; Juan M Bergua; Edo Vellenga; Chelo Rayón; Ricardo Parody; Javier de la Serna; Angel León; Jordi Esteve; Gustavo Milone; Guillermo Debén; Concha Rivas; Marcos González; Mar Tormo; Joaquín Díaz-Mediavilla; Jose D González; Silvia Negri; Elena Amutio; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Blood       Date:  2008-10-22       Impact factor: 22.113

10.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Authors:  Zhi-Xiang Shen; Zhan-Zhong Shi; Jing Fang; Bai-Wei Gu; Jun-Min Li; Yong-Mei Zhu; Jing-Yi Shi; Pei-Zheng Zheng; Hua Yan; Yuan-Fang Liu; Yu Chen; Yang Shen; Wen Wu; Wei Tang; Samuel Waxman; Hugues De Thé; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.